financetom
Business
financetom
/
Business
/
V-Mart Retail Unveils 17 New Stores, Closes 8 In Fourth Quarter of FY23
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
V-Mart Retail Unveils 17 New Stores, Closes 8 In Fourth Quarter of FY23
Apr 2, 2023 6:29 AM

Value fashion retailer V-Mart Retail, on Sunday said that it has opened 17 new stores, and closed 8 stores in the fourth quarter of Fiscal Year 2023. The Mumbai-based company revealed that it has opened 5 stores in Uttar Pradesh, 2 stores each in Assam, Telangana, Tamil Nadu and West Bengal, while one each in Gujarat, Kerala, Odisha and Madhya Pradesh. Further, V-Mart closed 8 stores during the same quarter. Of the 8 stores, 2 stores were closed in Uttar Pradesh, while one each in Bihar, Chennai, Karnataka, Madhya Pradesh, Gujarat and Manipur.

Share Market Live

NSE

The company, via a statement, said that the total number of stores now stands at 423 stores as on March at 31, 2023.

Earlier this month, Lalit Agarwal of V-Mart told CNBC-TV18 that people are adapting to rising inflation gradually. The company should be able to generate better sales from Q1FY24.

V-Mart reported its third quarter earnings in February, where the company’s profit plummeted 65 percent to Rs 20 crore against Rs 57.1 crore in the same quarter last year. However, revenue increased by over 12 percent to Rs 777 crore against Rs 692 crore in the same quarter last year.

The share price settled flat at Rs 2,141 on 31st March 2023, with 44 percent loss in trade during the financial year 2022-23.

Also Read: https://www.cnbctv18.com/retail/v-mart-aims-to-scale-limeroad-to-rs-50-crore-a-month-and-make-it-profitable-14970711.htm

(Edited by : Vahishta Unwalla)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Centerbridge Partners Completes Acquisition of MeridianLink
Centerbridge Partners Completes Acquisition of MeridianLink
Oct 24, 2025
MeridianLink becomes private company and delists from NYSE Silversmith Capital Partners makes minority investment in MeridianLink IRVINE, Calif.--(BUSINESS WIRE)-- Centerbridge Partners, L.P. (“Centerbridge”), a global investment firm with deep experience investing in financial services and technology, today announced the completion of its acquisition of MeridianLink, Inc. (“MeridianLink” or the “Company”), a leading provider of modern software platforms for financial...
Faraday Future Enters UAE Market Through Exclusive Deal
Faraday Future Enters UAE Market Through Exclusive Deal
Oct 24, 2025
Faraday Future Intelligent Electric Inc. ( FFAI ) shares are trading higher premarket on Friday after the company disclosed a deal for official entry into the United Arab Emirates (UAE) market. FFAI shares are trending higher. Find out why here The company penned a strategic cooperation with RAK Motors, an automotive dealer based in Ras Al Khaimah, one of the...
FOCUS-Novo Nordisk's new chairman has 'carte blanche' after board clear-out
FOCUS-Novo Nordisk's new chairman has 'carte blanche' after board clear-out
Oct 24, 2025
* Novo Nordisk Foundation has 77% vote share in Novo * Foundation clashed with board over pace of change * Current board chair, independent members stepping down * Foundation chair set also to become Novo Nordisk chairman * Novo is in fierce obesity drug battle with Eli Lilly ( LLY ) By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN, Oct 24...
Biogen licenses Vanqua Bio's immune disorder drug for up to $1.06 billion
Biogen licenses Vanqua Bio's immune disorder drug for up to $1.06 billion
Oct 24, 2025
Oct 24 (Reuters) - Biogen said on Friday it has gained global rights to privately held Vanqua Bio's experimental drug for up to $1.06 billion to expand its pipeline of immunology drugs. The oral drug targets a protein involved in various inflammatory disorders and is currently in preclinical testing, the drugmaker said. Biogen has been expanding into immunology and rare...
Copyright 2023-2026 - www.financetom.com All Rights Reserved